Follow-The-Filings

Security · featured owners

RANI

Rani Therapeutics Hldgs Inc. COM CL A Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • $16K
  • 1 reduce

holders

sorted by % of portfolio · long equity only · open a manager for their book

history
Farallon Capital Management 2026 Q2 0% Reduce −73.5% 20,700 $16K hist

1 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $1.03M $1.63M
Gross profit — — —
Gross margin — — —
Net income -$33.97M -$30.02M -$29.67M
Net margin * — -2920.0% -1817.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $50.85M $29.74M $53.32M
Total non-current assets * $7.07M $6.89M $5.3M
Total assets $57.92M $36.63M $58.62M
Total current liabilities $7.99M $19.89M $12.67M
Total non-current liabilities * $24.48M $13.25M $4.44M
Total equity $12.87M $1.99M $33.01M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$51.24M -$35.5M -$18.71M
Cash from investing $29.86M $19.81M -$7.03M
Cash from financing $233,000 $13.58M $40.3M
Net change in cash -$21.14M -$2.1M $14.56M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders

25Q4 26Q1

period archive